PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.
企業コードPAVM
会社名PAVmed Inc
上場日Jul 27, 2016
最高経営責任者「CEO」Aklog (Lishan)
従業員数39
証券種類Ordinary Share
決算期末Jul 27
本社所在地360 Madison Avenue
都市NEW YORK
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号10017
電話番号12129494319
ウェブサイトhttps://pavmed.com/
企業コードPAVM
上場日Jul 27, 2016
最高経営責任者「CEO」Aklog (Lishan)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし